Pancreatic VIPomas: Subject Review and One Institutional Experience

[1]  G. Nikou,et al.  VIPomas: an update in diagnosis and management in a series of 11 patients. , 2005, Hepato-gastroenterology.

[2]  P. Layer,et al.  Paralytic ileus responding to somatostatin therapy: First manifestation of a VIPoma , 1989, Digestive Diseases and Sciences.

[3]  R. Jensen,et al.  Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors , 1989, Digestive Diseases and Sciences.

[4]  L. Schiller.  Chronic diarrhea. , 2004, Gastroenterology.

[5]  R. Mansberg,et al.  VIPoma: a rare cause of a pancreatic mass. , 2004, Clinical Nuclear Medicine.

[6]  S. Peng,et al.  Diagnosis and Treatment of VIPoma in China: (Case Report and 31 Cases Review) Diagnosis and Treatment of VIPoma , 2004, Pancreas.

[7]  F. Lammert,et al.  Long-Term Survival After Diagnosis of Hepatic Metastatic VIPoma (Report of Two Cases with Disparate Courses and Review of Therapeutic Options) , 1999, Digestive Diseases and Sciences.

[8]  S. Okushiba,et al.  A Calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome , 2003, International journal of gastrointestinal cancer.

[9]  D. Klimstra,et al.  Malignant pancreatic tumors in childhood and adolescence: The Memorial Sloan-Kettering experience, 1967 to present. , 2002, Journal of pediatric surgery.

[10]  L. Tillotson,et al.  A 32-year-old man with copious, watery diarrhea. , 2001, North Carolina medical journal.

[11]  P. Ros,et al.  Dynamic gadolinium-enhanced MR imaging of pancreatic VIPoma in a patient with Verner-Morrison syndrome , 2001, European Radiology.

[12]  T. Chen,et al.  Surgical treatment of pancreatic vasoactive intestinal polypeptide-secreting tumor: a case report. , 2001, Hepato-Gastroenterology.

[13]  K. Öberg.  Chemotherapy and biotherapy in the treatment of neuroendocrine tumours , 2001 .

[14]  G. Chandy,et al.  VIPoma of pancreas in a child. , 2000, Indian Journal of Gastroenterology.

[15]  J. W. Thomason,et al.  Somatostatin Receptor Scintigraphy: The Definitive Technique for Characterizing Vasoactive Intestinal Peptide–Secreting Tumors , 2000, Clinical nuclear medicine.

[16]  D. Cullen,et al.  Pancreatic vasoactive intestinal polypeptide‐oma as a cause of secretory diarrhoea , 2000, Journal of gastroenterology and hepatology.

[17]  U. Mueller-Lisse,et al.  Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. , 2000, Radiology.

[18]  L. Schiller,et al.  AGA technical review on the evaluation and management of chronic diarrhea. , 1999, Gastroenterology.

[19]  N. Ectors.  Pancreatic endocrine tumors: diagnostic pitfalls. , 1999, Hepato-gastroenterology.

[20]  R. Jensen,et al.  Pancreatic endocrine tumors: recent advances. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  S. D. Lee,et al.  Functional pancreatic islet cell tumors with liver metastasis: the role of cytoreductive surgery and transcatheter arterial chemoembolization: a report of five cases. , 1998, Zhonghua yi xue za zhi = Chinese medical journal; Free China ed.

[22]  J. K. Martin,et al.  Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. , 1998, Surgery.

[23]  J. Soga,et al.  Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. , 1998, Journal of experimental & clinical cancer research : CR.

[24]  T. Adrian,et al.  Life threatening diarrhoea ultimately cured by surgery. , 1998, European Journal of Gastroenterology and Hepathology.

[25]  P Hübsch,et al.  Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  J Coste,et al.  Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography. , 1998, AJR. American journal of roentgenology.

[27]  P. Flemming,et al.  Metastatic pancreatic VIPoma: deteriorating clinical course and successful treatment by liver transplantation. , 1998, Zeitschrift fur Gastroenterologie.

[28]  R. Semelka,et al.  MR imaging of metastatic pancreatic VIPoma. , 1997, Magnetic resonance imaging.

[29]  A. Kirkpatrick,et al.  Surgical treatment of pancreatic cholera: a case report. , 1996, Canadian journal of surgery. Journal canadien de chirurgie.

[30]  J. Slavin,et al.  Massive Amyloid Deposition In Pancreatic Vipoma: A case report , 1996, Pathology.

[31]  A. Vinik,et al.  Clinical review 72: diagnosis and management of functioning islet cell tumors. , 1995, The Journal of clinical endocrinology and metabolism.

[32]  T. Bonner,et al.  Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. , 1994, Endocrinology.

[33]  J. Villanueva-Meyer,et al.  Tc-99m Sestamibi Imaging of a Pancreatic VIPoma and Parathyroid Adenoma in a Patient With Multiple Type I Endocrine Neoplasia , 1994, Clinical nuclear medicine.

[34]  R. Reznek,et al.  Imaging islet cell tumours. , 1994, Clinical radiology.

[35]  S. Wells,et al.  Stimulation of vasoactive intestinal peptide and neurotensin secretion by pentagastrin in a patient with VIPoma syndrome. , 1994, Surgery.

[36]  J. Fahrenkrug.  Transmitter role of vasoactive intestinal peptide. , 1993, Pharmacology & toxicology.

[37]  A. Antonelli,et al.  Calcitonin, as SMS 201–995, ameliorates the VIPoma syndrome , 1993, Journal of endocrinological investigation.

[38]  J. Cameron,et al.  Pancreaticoduodenectomy for selected pancreatic endocrine tumors. , 1993, Surgery, gynecology & obstetrics.

[39]  D. Bani,et al.  Immunocytochemical and Ultrastructural Abnormalities of Islet Tissue in Patients with VIP‐Producing Tumors of the Pancreas , 1992, Pancreas.

[40]  F. Cavagnini,et al.  Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome , 1991, Journal of endocrinological investigation.

[41]  J. Utsunomiya,et al.  Vipoma of the pancreas complicating ulcerative colitis. , 1991, American Journal of Gastroenterology.

[42]  A. Vinik,et al.  Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation. , 1990, Radiology.

[43]  P. Giraud,et al.  CHARACTERIZATION OF AN α‐AMIDATING ACTIVITY IN A HUMAN PANCREATIC TUMOUR SECRETING VASOACTIVE INTESTINAL PEPTIDE (VIP) , 1990, Clinical endocrinology.

[44]  M. Losowsky,et al.  Treatment of metastatic Vipoma by liver transplantation. , 1990, Clinical transplantation.

[45]  C. Christensen.  The somatostatin analogue SMS 201-995 in long-term treatment of vipoma. Case report. , 1989, Acta chirurgica Scandinavica.

[46]  N. Samaan,et al.  Somatostatin analogue: use in the treatment of vipoma with hypercalcemia. , 1989, The American journal of medicine.

[47]  H. Mekhjian,et al.  Medical therapy of VIPomas. , 1989, Endocrinology and metabolism clinics of North America.

[48]  G. Griffioen,et al.  MR, CT, and ultrasound findings of metastatic vipoma in pancreas. , 1989, Journal of computer assisted tomography.

[49]  M. Papotti,et al.  A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report , 1988, Cancer.

[50]  G. Thompson,et al.  Islet cell carcinomas of the pancreas: a twenty-year experience. , 1988, Surgery.

[51]  M. Donowitz,et al.  Pancreatic cholera syndrome due to a vasoactive intestinal polypeptide-producing tumor: further insights into the pathophysiology. , 1988, Gastroenterology.

[52]  S. Friesen.  Update on the diagnosis and treatment of rare neuroendocrine tumors. , 1987, The Surgical clinics of North America.

[53]  H. Mekhjian,et al.  VIPoma syndrome. , 1987, Seminars in oncology.

[54]  S. Bloom,et al.  Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. , 1985, Gastroenterology.

[55]  J. Behar,et al.  Vasoactive intestinal polypeptide. A neurotransmitter for lower esophageal sphincter relaxation. , 1984, The Journal of clinical investigation.

[56]  J. Holst,et al.  Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in control of fluid and bicarbonate secretion , 1984, Regulatory Peptides.

[57]  M. G. Kane,et al.  Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. , 1983, The New England journal of medicine.

[58]  S. Bloom,et al.  Morphologic patterns and diagnostic criteria of VIP‐producing endocrine tumors. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases , 1983, Cancer.

[59]  J. Fahrenkrug,et al.  Vasoactive intestinal polypeptide , 1980, Trends in Neurosciences.

[60]  P. Robberecht,et al.  Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. , 1976, The Journal of biological chemistry.

[61]  J. Polak,et al.  VASOACTIVE INTESTINAL PEPTIDE AND WATERY-DIARRHŒA SYNDROME , 1973 .

[62]  J. Polak,et al.  Vasoactive intestinal peptide and watery-diarrhoea syndrome. , 1973, Lancet.

[63]  M. Grossman,et al.  Intestinal Secretion: Stimulation by Peptides , 1971, Science.

[64]  A. Morrison,et al.  Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. , 1958, The American journal of medicine.

[65]  M. K. Alexander,et al.  ISLET-CELL TUMOUR OF THE PANCREAS WITH PEPTIC ULCERATION, DIARRHŒA, AND HYPOKALÆMIA , 1957 .

[66]  Attwater Hl.  Surgery of urethral stricture. , 1948 .